We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
COVID-19 Infection in Patients with Comorbidities: Clinical and Immunological Insight.
- Authors
El-Badawy, Omnia; Elsherbiny, Nahla M.; Abdeltawab, Doaa; Magdy, Doaa M.; Bakkar, Lamees M.; Hassan, Shimaa A.; Hassan, Elham A.; Thabet, Ahmed M.; Ashmawy, Ahmed M.; Moustafa, Ehab F.; Abbas, Wael A.; Ahmad, Ahmad Bahieldeen; Rayan, Amal; Saad, Khaled; Elhoufey, Amira; Hussein, Hosni A. M.; Thabet, Ali A.; Zahran, Asmaa M.
- Abstract
Aim: Our study's objectives were to study the clinical and laboratory characteristics that may serve as biomarkers for predicting disease severity, IL-10 levels, and frequencies of different T cell subsets in comorbid COVID-19 patients. Methods: Sixty-two hospitalized COVID-19 patients with comorbidities were assessed clinically and radiologically. Blood samples were collected to assess the T lymphocyte subsets by flow cytometry and IL-10 levels by ELISA. Results: The most common comorbidities observed in COVID-19 patients were diabetes mellitus (DM), hypertension, and malignancies. Common symptoms and signs included fever, cough, dyspnea, fatigue, myalgia, and sore throat. CRP, ferritin, D dimer, LDH, urea, creatinine, and direct bilirubin were significantly increased in patients than controls. Lymphocyte count and CD4+ and CD8+ T-cells were significantly decreased in comorbid COVID-19 patients, and CD25 and CD45RA expression were increased. CD4+ and CD8+ regulatory T cells (Tregs) and IL-10 levels were significantly decreased in patients. Conclusions: Many parameters were found to be predictive of severity in the comorbid patients in our study. Significant reductions in the levels and activation of CD4+ and CD8+ T-cells were found. In addition, CD4+ and CD8+ Tregs were significant decreased in patients, probably pointing to a prominent role of CD8+ Tregs in dampening CD4+ T-cell activation.
- Subjects
COVID-19; REGULATORY T cells; LYMPHOCYTE subsets; T cells; SYMPTOMS; THROAT diseases
- Publication
Clinical & Applied Thrombosis/Hemostasis, 2022, Vol 28, p1
- ISSN
1076-0296
- Publication type
Article
- DOI
10.1177/10760296221107889